Interim results from ASTM’s US Phase 2b RESTORE-CLI trial will be presented by the principal investigator, Richard J. Powell, MD, section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH at the 2010 Vascular Annual Meeting on 6/11/10 in Boston, MA. Read more…
SSS.V reports no statistical differences between the groups and but, the top-line primary endpoint results for the modified REGENESIS P2b stroke trial of NTx (R)-265 in acute stroke Read more…
Australia’s MSB received clearance from the US’s FDA to begin Phase 2 clinical trials of its “off-the-shelf” or allogeneic stem cell product NeoFuse™ for fusion of the cervical spine in the neck. Read more…
We are all looking for any signal that will propel a stock and one major indicator is the CEO investing his own money. Timothy Mayleben, CEO of ASTM filed another Form 4, this week with the SEC wiich is his 2nd open market purchase since becoming CEO in 12/09. Read more…
The Vatican praised scientists, who had created the world’s first synthetic cell, calling it an “interesting result” that could help cure disease. Read more…
ASTM has been volatile based on the recent market depreciation and is held at an extremely low stock price in relation to the market comps and 3 late stage clinical trials targeting niche cardiovascular indications. I updated the model post the last few weeks of downward pricing implying a valuation of $3.56 given the fully diluted shares outstanding with a Sum of the Parts estimation of $5.71 (discounted 20%) which is significantly above the current price of $1.42 and market cap of $40.12 M. Read more…
A team of scientists at the J. Craig Venter Institute announced that they have successfully created a living organism with a completely synthetic genome. Read more…
This prospectus relates to the public offering of up to 89.9 M shares of common stock, par value $.001 per share of Advanced Cell Technology (ACT or ACTC.OB). ACT entered into multiple convertible promissory notes and 3 unsecured convertible notes to JMJ Financial; some with a “Make Whole Amount” to the balance of the applicable JMJ Notes. However, ACT will not receive any of the proceeds from the sale (basically registering the shares) but, will pay the expenses of registering these shares. Read more…
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its 3 official Requests for Applications (RFAs) during the FY10 funding cycle. The board of directors of the Maryland Technology Development Corporation (TEDCO) reviewed the Commission’s recommendations and approved 42 projects totaling $11.7 M in funding Read more…
ASTM announced the appointments of Sharon Watling, Pharm.D, as VP, Clinical and Regulatory, and Ronnda L. Bartel, Ph.D, VP, Chief Scientific Officer (formerly VP Technical Operations). Read more…
